Pronounced Regional Variation in Esketamine and Ketamine Prescribing to US Medicaid Patients

References

• Aan Het Rot, M., C. A. Zarate, C. Ds, and S. J. Mathew. 2012. Ketamine for depression: Where do we go from here? Biological Psychiatry 72 (7):537–47. doi:10.1016/j.biopsych.2012.05.003.
   PubMed Web of Science ®Google Scholar
• Acevedo-Diaz, E. E., G. W. Cavanaugh, D. Greenstein, C. Kraus, B. Kadriu, L. Park, and C. A. Zarate Jr. 2020. Can ‘floating’predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. Journal of Psychiatric Research 130:280–85. doi:10.1016/j.jpsychires.2020.06.012.
   PubMed Web of Science ®Google Scholar
• Agboola, F., S. J. Atlas, D. R. Touchette, K. Fazioli, and S. D. Pearson. 2020. The effectiveness and value of esketamine for the management of treatment-resistant depression: A summary from the institute for clinical and economic review’s midwest comparative effectiveness public advisory council. Journal of Managed Care and Specialty Pharmacy 26 (1):16–20. doi:10.18553/jmcp.2020.26.1.16.
   PubMed Web of Science ®Google Scholar
• Andrade, C. 2017. Ketamine for depression, 4: In what dose, at what rate, by what route, for how long, and at what frequency? The Journal of Clinical Psychiatry 78 (7):e852–57. doi:10.4088/JCP.17f11738.
   PubMed Web of Science ®Google Scholar
• Black Parker, C., W. V. McCall, E. V. Spearman-McCarthy, P. Rosenquist, and N. Cortese. 2021. Clinicians’ racial bias contributing to disparities in electroconvulsive therapy for patients from racial-ethnic minority groups. Psychiatric Services 72:684–90. doi:10.1176/appi.ps.202000142.
   PubMed Web of Science ®Google Scholar
• Brendle, M., R. Robison, and D. C. Malone. 2022. Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates. Journal of Affective Disorders 319:388–96. doi:10.1016/j.jad.2022.09.083.
   PubMed Web of Science ®Google Scholar
• Brezina, K. 2017. ELEKT-D: Electroconvulsive Therapy (ECT) vs. ketamine in patients with treatment resistant depression (TRD)Vol. NCT03113968. https://clinicaltrials.gov/ct2/show/NCT03113968
   Google Scholar
• Clin Calc. The top 300 of 2019. Accessed May 6, 2022. https://clincalc.com/DrugStats/Top300Drugs.aspx.
   Google Scholar
• Correia-Melo, F. S., G. C. Leala, F. Vieiraa, A. P. Jesus-Nunesa, R. P. Mello, R. Magnavita, A. T. Caliman-Fontes, M. V. F. Echegaray, I. D. Bandeira, S. S. Silva, et al. 2020. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double blind, non-inferiority study. Journal of Affective Disorders 264:527–34. doi:10.1016/j.jad.2019.11.086.
   PubMed Web of Science ®Google Scholar
• Dadiomov, D., and K. Lee. 2019. The effects of ketamine on suicidality across various formulations and study settings. Mental Health Clin 9 (1):48–60. doi:10.9740/mhc.2019.01.048.
   PubMedGoogle Scholar
• Dodd, E., and M. DeSilva 2018. Ketamine versus electroconvulsive therapy in depression. NCT03674671. Accessed February 17, 2023. https://clinicaltrials.gov/ct2/show/NCT03674671
   Google Scholar
• Duman, R. S. 2018. Ketamine and rapid-acting antidepressants: A new era in the battle against depression and suicide. F1000 Research 7:659. doi:10.12688/f1000research.14344.1.
   Google Scholar
• Espinoza, R., and C. Kellner. 2022. Electroconvulsive therapy. The New England Journal of Medicine 386:667–72. doi:10.1056/NEJMra2034954.
   PubMed Web of Science ®Google Scholar
• Fukumoto, K., H. Toki, M. Iijima, T. Hashihayata, J. I. Yamaguchi, K. Hashimoto, and S. Chaki. 2017. Antidepressant potential of (R)-ketamine in rodent models: Comparison with (S)-ketamine. Journal of Pharmacology & Experimental Therapeutics 361:9–16. doi:10.1124/jpet.116.239228.
   PubMed Web of Science ®Google Scholar
• Gálvez, V., A. Li, C. Huggins, P. Glue, P. Martin, A. A. Somogyi, A. Alonzo, A. Rodgers, P. B. Mitchell, and C. K. Loo. 2018. Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology 32 (4):397–407. doi:10.1177/0269881118760660.
   PubMed Web of Science ®Google Scholar
• Gerb, S. A., J. E. Cook, A. E. Gochenauer, C. Y. Young, L. K. Fulton, A. W. Grady, and K. B. Freeman. 2019. Ketamine tolerance in Sprague–Dawley rats after chronic administration of ketamine, morphine, or cocaine. Comparative Medicine 69:29–34. doi:10.30802/AALAS-CM-18-000053.
   PubMed Web of Science ®Google Scholar
• Howland, R. H. 2008. Sequenced treatment alternatives to relieve depression (STAR*D). Part 2: Study outcomes. Journal of Psychosocial Nursing & Mental Health Services 46 (10):21–24. doi:10.3928/02793695-20081001-05.
   Web of Science ®Google Scholar
• Jones, K. C., J. L. Salemi, D. Dongawar, M. E. Kunik, S. M. Rodriguez, T. H. Quach, and H. M. Salihu. 2019. Racial/ethnic disparities in receipt of electroconvulsive therapy for elderly patients with a principal diagnosis of depression in inpatient settings. The American Journal of Geriatric Psychiatry 27:3 (3):266–78. doi:10.1016/j.jagp.2018.11.007.
   Web of Science ®Google Scholar
• Lapidus, K. A., C. F. Levitch, A. M. Perez, J. W. Brallier, M. K. Parides, L. Soleimani, A. Feder, D. V. Iosifescu, D. S. Charney, and J. W. Murrough. 2014. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry 76 (12):970–76. doi:10.1016/j.biopsych.2014.03.026.
   PubMed Web of Science ®Google Scholar
• Larkin, G. L., and A. L. Beautrais. 2017. Retraction of publication: A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. International Journal of Neuropsychopharmacology 20 (7):611. doi:10.1093/ijnp/pyx035.
   PubMed Web of Science ®Google Scholar
• Maldi, K. D., P. Asellus, A. Myléus, and F. Norström. 2021. Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression. BMC Psychiatry 21:610. doi:10.1186/s12888-021-03601-8.
   PubMed Web of Science ®Google Scholar
• McIntyre, R. S., J. D. Rosenblat, C. B. Nemeroff, G. Sanacora, J. W. Murrough, M. Berk, E. Brietzke, S. Dodd, P. Gorwood, R. Ho, et al. 2021. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. The American Journal of Psychiatry 178:383–99. doi:10.1176/appi.ajp.2020.20081251.
   PubMed Web of Science ®Google Scholar
• Medicaid. 2022. State drug utilization data. Accessed February 17, 2023. https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html
   Google Scholar
• Murrough, J. W., D. V. Iosifescu, L. C. Chang, R. K. Al Jurdi, C. E. Green, A. M. Perez, S. Iqbal, S. Pillemer, A. Foulkes, A. Shah, et al. 2013. Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. The American Journal of Psychiatry 170 (10):1134–42. doi:10.1176/appi.ajp.2013.13030392.
   PubMed Web of Science ®Google Scholar
• Nischal, A., A. Tripathi, A. Nischal, and J. K. Trivedi. 2012. Suicide and antidepressants: What current evidence indicates. Mens Sana Monographs 10 (1):33–44. doi:10.4103/0973-1229.87287.
   PubMedGoogle Scholar
• Pharmacoeconomic report: Esketamine hydrochloride (Spravato): (Janssen Inc.): Indication: major depressive disorder in adults. 2021. Appendix 1, Cost Comparison Table. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, Apr. https://www.ncbi.nlm.nih.gov/books/NBK572205.
   Google Scholar
• Qiu, Y., and G. Du 2020. The effect of S-ketamine for patients undergoing electroconvulsive therapy (ECT). NCT04399070.
   Google Scholar
• Retraction Watch. The Retraction Watch Database. 2022. New York: The Center for Scientific Integrity, Accessed January 2, 2022. http://retractiondatabase.org/.
   Google Scholar
• Ross, E. L., and D. L. Soeteman. 2020. Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States. Psychiatric Services 71 (10):988–97. doi:10.1176/appi.ps.201900625.
   PubMed Web of Science ®Google Scholar
• Short, B., J. Fong, V. Galvez, W. Shelker, and C. K. Loo. 2018. Side-effects associated with ketamine use in depression: A systematic review. The Lancet Psychiatry 5 (1):65–78. doi:10.1016/S2215-0366(17)30272-9.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. 2022. Suicide. National Institute of Mental Health. Accessed February 11, 2022. https://www.nimh.nih.gov/health/statistics/suicide.
   Google Scholar
• Watts, B. V., T. Peltzman, and B. Shiner. 2022 Apr 13. Electroconvulsive therapy and death by suicide. The Journal of Clinical Psychiatry 83(3):21m13886. 10.4088/JCP.21m13886. PMID: 35421285.
   PubMed Web of Science ®Google Scholar
• Yang, C., Y. Shirayama, J. Zhang, Q. Ren, W. Yao, M. Ma, C. Dong, and K. Hashimoto. 2015. R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects. Translational Psychiatry 5:e632. doi:10.1038/tp.2015.136.
   PubMed Web of Science ®Google Scholar
• Yard, E., L. Radhakrishnan, M. F. Ballesteros, M. Sheppard, A. Gates, Z. Stein, K. Hartnett, A. Kite-Powell, L. Rodgers, J. Adjemian, et al. 2021. Emergency department visits for suspected suicide attempts among persons aged 12–25 years before and during the COVID-19 pandemic — United States, January 2019–may 2021. MMWR Morbidity Mortality Weekly Report 70:888–94. doi:http://dx.doi.org/10.15585/mmwr.mm7024e1externalicon.
   PubMed Web of Science ®Google Scholar
• Zarate, C. A., Jr, N. E. Brutsche, L. Ibrahim, J. Franco-Chaves, N. Diazgranados, A. Cravchik, J. Selter, C. A. Marquardt, V. Liberty, and D. A. Luckenbaugh. 2012. Replication of ketamine’s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biological Psychiatry 71 (11):939–46. doi:10.1016/j.biopsych.2011.12.010.
   PubMed Web of Science ®Google Scholar
• Zarate, C. A., J. B. Singh, P. J. Carlson, N. E. Brutsche, R. Ameli, D. A. Luckenbaugh, D. S. Charney, and H. K. Manji. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63 (8):856–64. doi:10.1001/archpsyc.63.8.856.
   PubMed Web of Science ®Google Scholar
• Zhang, J., S. Li, and K. Hashimoto. 2014. R (−)-ketamine shows greater potency and longer lasting antidepressant effects than s (+)-ketamine. Pharmacology Biochemistry & Behavior 116:137–41. doi:10.1016/j.pbb.2013.11.033.
   PubMed Web of Science ®Google Scholar